Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 20, Issue -, Pages S499-S512Publisher
IOS PRESS
DOI: 10.3233/JAD-2010-100504
Keywords
Amyloid-beta; Amyloid-beta precursor protein; mitochondrial therapeutics; synaptic pathology
Categories
Funding
- National Institutes of Health [AG028072, AG026051, RR00163]
- Alzheimer's Association [IIRG-09-92429]
- Medivation, Inc.
- NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG028072, R03AG026051] Funding Source: NIH RePORTER
Ask authors/readers for more resources
This article reviews the role of amyloid-beta (A beta) and mitochondria in synaptic damage and cognitive decline found in patients with Alzheimer's disease (AD). Recent molecular, cellular, animal model, and postmortem brain studies have revealed that A beta and mitochondrial abnormalities are key factors that cause synaptic damage and cognitive decline in AD. A beta is reported to accumulate in subcellular compartments and to impair the normal function of neurons in AD patients. Further, recent studies using biochemical methods and electron microscopy have revealed that the accumulation of A beta at nerve terminals affect synaptic activities, including the release of neurotransmitters and synaptic vesicles. Recent studies of the relationship between mitochondria and A beta in AD patients suggest that in mitochondria, structural changes caused by A beta result in increased mitochondrial fragmentation, decreased mitochondrial fusion, mitochondrial dysfunction, and synaptic damage. This paper discusses the latest research on A beta, mitochondria, age-dependent factors of AD in the brain, and synaptic damage in AD. This paper also briefly discusses potential mitochondrial therapeutics in the treatment of patients with AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available